one
TREATMENT OF NEUROLOGICAL DISEASE
Last updated:
Abstract:
The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H- dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding of Cu/Zn Superoxide Dismutase (SOD1) or mediated by astrocyte toxicity affecting motor neuron survival.
Status:
Application
Type:
Utility
Filling date:
18 Oct 2019
Issue date:
18 Nov 2021